Table 2.
Drug-related TEAEs by CTC grade (≥10%)
| Gal + TMZ/RTX (N = 40) | TMZ/RTX (N = 16) | |||||
|---|---|---|---|---|---|---|
| Grade 1–2 | Grade ≥3 | All Grade | Grade 1–2 | Grade ≥3 | All Grade | |
| Laboratory Event | ||||||
| Platelet count decreased | 12 (30.0) | 6 (15.0) | 18 (45) | 3 (18.8) | 1 (6.3) | 4 (25.1) |
| Lymphocyte count decreased | 5 (12.5) | 8 (20.0) | 13 (32.5) | 2 (12.5) | 1 (6.3) | 3 (18.8) |
| White blood cells decreased | 8 (20.0) | 4 (10.0) | 12 (30) | 1 (6.3) | 0 (0.0) | 1 (6.3) |
| ALT increased | 4 (10.0) | 3 (7.5) | 7 (17.5) | 2 (12.5) | 0 (0.0) | 2 (12.5) |
| Neutrophil count decreased | 5 (12.5) | 2 (5.0) | 7 (17.5) | 2 (12.5) | 0 (0.0) | 2 (12.5) |
| Anaemia | 6 (15.0) | 0 (0.0) | 6 (15) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Non-laboratory Event | ||||||
| Fatigue | 24 (60.0) | 1 (2.5) | 25 (62.5) | 6 (37.5) | 0 (0.0) | 6 (37.5) |
| Nausea | 21 (52.5) | 0 (0.0) | 21 (52.5) | 8 (50.0) | 1 (6.3) | 9 (56.3) |
| Constipation | 16 (40.0) | 0 (0.0) | 16 (40) | 4 (25.0) | 0 (0.0) | 4 (25.0) |
| Alopecia | 16 (40.0) | 0 (0.0) | 16 (40) | 3 (18.8) | 0 (0.0) | 3 (18.8) |
| Vomiting | 11 (27.5) | 1 (2.5) | 12 (30) | 5 (31.3) | 0 (0.0) | 5 (31.3) |
| Decreased Appetite | 8 (20.0) | 0 (0.0) | 8 (20) | 2 (12.5) | 0 (0.0) | 2 (12.5) |
| Headache | 6 (15.0) | 0 (0.0) | 6 (15) | 2 (12.5) | 0 (0.0) | 2 (12.5) |
| Dyspepsia | 5 (12.5) | 0 (0.0) | 5 (12.5) | 1 (6.3) | 0 (0.0) | 1 (6.3) |
| Weight decreased | 5 (12.5) | 0 (0.0) | 5 (12.5) | 1 (6.3) | 0 (0.0) | 1 (6.3) |
To note: data given as No. (%) unless otherwise indicated
ALT alanine aminotransferase, Gal galunisertib, TMZ temozolomide, RTX radiation, TEAE treatment-emergent adverse events